1. Home
  2. REX vs NUVB Comparison

REX vs NUVB Comparison

Compare REX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REX American Resources Corporation

REX

REX American Resources Corporation

HOLD

Current Price

$43.94

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$4.92

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REX
NUVB
Founded
1980
2018
Country
United States
United States
Employees
N/A
307
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
REX
NUVB
Price
$43.94
$4.92
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
159.3K
4.3M
Earning Date
05-27-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.56
N/A
Revenue
$650,487,000.00
N/A
Revenue This Year
$19.45
$203.82
Revenue Next Year
N/A
$58.18
P/E Ratio
$76.79
N/A
Revenue Growth
1.24
N/A
52 Week Low
$30.02
$1.57
52 Week High
$64.95
$9.75

Technical Indicators

Market Signals
Indicator
REX
NUVB
Relative Strength Index (RSI) 37.58 53.69
Support Level $31.24 $4.07
Resistance Level $49.85 $5.16
Average True Range (ATR) 2.21 0.37
MACD -0.63 0.00
Stochastic Oscillator 15.22 39.52

Price Performance

Historical Comparison
REX
NUVB

About REX REX American Resources Corporation

REX American Resources Corp operates as a holding company that engages in investments in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include Ethanol, dried distillers grains, modified distillers grains, Distillers corn oil, Modified distillers grains, and Other.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: